WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKD
Peter Rossing(Steno Diabetes Centers), Katherine R. Tuttle(Providence Regional Medical Center Everett), Zhichao Sun(Boehringer Ingelheim (Japan)), Dick de Zeeuw(University Medical Center Groningen), Shimoli Shah(Boehringer Ingelheim (Germany)), Juliane Meyerhoff(Boehringer Ingelheim (Germany)), Lisa Cronin(Boehringer Ingelheim (Germany)), Sibylle J. Hauske(Heidelberg University), Hiddo J.L. Heerspink(University Medical Center Groningen)
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k